Download this file (CHART_Library_PowerPoint_Tool.ppt)

750 views
680 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
750
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Download this file (CHART_Library_PowerPoint_Tool.ppt)

  1. 1. CHART LIBRARY POWERPOINT TOOL The best way to find out what information a particular CHART library can give you, is to take a look at the summary sheet. To do this, simply click on one of the libraries below. MYOCARDIAL INFARCTION AND ACUTE CORONARY SYNDROME SAFER PRESCRIBING GRASP AF (ATRIAL FIBRILLATION) HEROIN MISUSE MMR VACCINATION PNEUMOCOCCAL VACCINATION LOCAL DELIVERY PLAN (SMOKING & OBESITY) IM&T DES SPARE BUTTON AWAITING FOR ANY NEW LIBRARY SUMMARY, CHARTS, DATASHEET EXAMPLE CHART ONLINE CHART & MIQUEST OVERVIEW
  2. 2. HOW CHART & MIQUEST WORK BACK TO MENU Click the mouse to see the CHART process step by step
  3. 3. HOW CHART & MIQUEST WORK CLINICAL SYSTEM CLINICAL SYSTEM DATABASE PRIMIS+ WEBSITE MIQUEST INTERPRETER BACK TO MENU PRACTICE COMPUTER CHART SOFTWARE LIBRARIES SWINE FLU MIACS MIACS SUMMARY SHEET MIACS DATA SHEET MIACS GRAPHS CHART QUERY LIBRARIES SAFER PRESCRIBING, FLU, SWINE FLU, MIACS, MMR HEROIN MISUSE, LDP CHART SOFTWARE Click the mouse to see the CHART process step by step MIACS Queries on disk/pen drive/network MIACS Responses on disk/pen drive/network
  4. 4. CHART LIBRARIES The best way to find out what information a particular CHART library can give you, is to take a look at the summary sheet. To do this, simply click on one of the libraries below. MYOCARDIAL INFARCTION AND ACUTE CORONARY SYNDROME SAFER PRESCRIBING GRASP AF (ATRIAL FIBRILLATION) HEROIN MISUSE MMR VACCINATION PNEUMOCOCCAL VACCINATION LOCAL DELIVERY PLAN (SMOKING & OBESITY) IM&T DES SPARE BUTTON AWAITING FOR ANY NEW LIBRARY SUMMARY, CHARTS, DATASHEET EXAMPLE CHART ONLINE CHART & MIQUEST OVERVIEW
  5. 5. HOW CHART & MIQUEST WORK 1) Download CHART Software and CHART Query Libraries free from PRIMIS+ Website and install on Practice Computer – (One off process) 2) Create CHART MIQUEST Queries and load them into MIQUEST Interpreter on Clinical System 3) MIQUEST Interpreter interrogates Clinical System Database 4) Obtain CHART MIQUEST Responses from MIQUEST Interpreter on Clinical System 5) Load CHART MIQUEST RESPONSES into CHART Software and see SUMMARY SHEET, DATA SHEET and GRAPHS BACK TO MENU Queries on disk/pen drive/network Responses on disk/pen drive/network CLINICAL SYSTEM DATABASE PRIMIS+ WEBSITE CHART SOFTWARE CHART QUERY LIBRARIES PRACTICE COMPUTER CHART SOFTWARE CHART QUERY LIBRARIES PRACTICE COMPUTER SUMMARY SHEET DATA SHEET GRAPHS MIQUEST INTERPRETER 1 2 3 3 4 5
  6. 6. MI & ACS The NICE MIACS guidance covers such things as dietary advice, exercise advice,referral to cardiac rehabilitation, smoking advice and the use of specific drugs. One area that many PCTs may also have an interest in is the appropriate use of Clopidogrel, an expensive drug used for varying lengths of time after an infarct. The audit will enable practices to see that they are using it in accordance with the guidance. To take a look at a particular area, please click the appropriate button above. POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME Population Advice & Procedures Medication Heart Failure Clopidogrel MI by Category ACS by Category
  7. 7. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME TOTAL PRACTICE POPULATION 10620 Population Latest MI in last 12 months Latest MI over 12 months ago TOTAL No of patients who have had an MI 7 130 137 Percent of Practice Population 0.07% 1.22% 1.29%
  8. 8. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME NO OF PATIENTS PERCENTAGE OF PATIENTS Advice and Procedures Post MI Latest MI in last 12 months Latest MI over 12 months ago TOTAL Latest MI in last 12 months Latest MI over 12 months ago TOTAL No of patients offered exercise advice since last MI 1 37 38 14.3% 28.5% 28% No of patients whose latest smoking status shows them as smokers 2 11 13 28.6% 8.5% 8% No of patients given advice to quit smoking since MI 1 53 54 14.3% 40.8% 41% No of patients referred to cessation service since MI 0 0 0 0.0% 0.0% 0% No of patients offered dietary advice since last MI 1 33 34 14.3% 25.4% 25% No of patients offered Cardiac Rehabilitation since last MI 1 1 2 14.3% 0.8% 1% No of patients recorded as having Bypass Surgery since last MI 1 5 6 14.3% 3.8% 4% No of patients recorded as having Angioplasty since last MI 1 8 9 14.3% 6.2% 6% No of patients recorded as having a Stent inserted since last MI 3 16 19 42.9% 12.3% 12%
  9. 9. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME Medication Post MI ACEI Aspirin BETA BLOCKER STATIN No of patients with issue for each drug in last three months 98 94 89 106 No of patients with contra-indication code for each drug 1 6 12 Percent on each drug out of all those post MI minus those with contra-indication 72% 72% 71% 79% Overall Treatment 4 of above drugs 3 of above drugs 2 of above drugs 1 of above drugs 0 of above drugs TOTAL No of Post MI patients on or with conta-indication to the combination of drugs 47 53 26 9 2 137
  10. 10. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME Heart Failure Total Licensed Aldosterone Antagonist issued in last 3 months Potassium checked in last 3 months Patients who have had an MI and Left Ventricular Systolic Dysfunction 6 1 2
  11. 11. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME It is not useful for these patients so we are wasting resource by giving it to them. EXPLANATION Clopidogrel is an expensive drug. It is beneficial for patients in categories 1 to 3. It is not beneficial for patients in categories 5 to 9. Because the type of MI is unspecified, we do not know whether it will be beneficial for patients in category 4. Therefore the patients represented by red numbers should be on clopidogrel and are not. The patients represented by blue numbers are on clopidogrel even though it is of no benefit to them. The patients represented by green numbers need investigating further before we know whether their clopidogrel status is correct. Diagnostic Categories v Current Clopidogrel Treatment Treatment Advised Clopidogrel issued in last 3 months Clopidogrel not issued 1 STEMI in last 1 month Yes 0 0 2 NSTEMI in last 12 months Yes 2 0 3 Stent in last 12 months Yes 3 4 4 Unspecified MI in last 12 months (Does not distinguish STEMI from NSTEMI Ambiguous 1 0 5 STEMI more than 1 month ago No 2 5 6 NSTEMI more than 12 months ago No 0 5 7 Stent more than 12 months ago No 3 25 8 Unspecified MI more than 12 months ago No 5 98 9 ACS Only No 3 10
  12. 12. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME EXPLANATION To treat an MI correctly, you need to know what type of MI it is. The patients represented by red numbers , particularly hose with an MI in the last 12 months, would need to have a more specific diagnosis put on their medical record. Recording of Latest Myocardial Infarction by Category No in last 12 months No more than 12 months ago Positional i.e. Antero-Lateral or Posterior 1 8 Q Wave 0 0 Non Q Wave 0 1 Sub-Endocardial 0 2 STEMI 1 3 NSTEMI 3 4 Micro-Infarction 0 0 MI Aborted 0 0 Unspecified 2 112 TOTAL 7 130
  13. 13. MI & ACS POPULATION ADVICE & PROCEDURES MEDICATION HEART FAILURE CLOPIDOGREL USAGE MI BY CATEGORY ACS BY CATEGORY CHOOSE ANOTHER LIBRARY MI & ACS HOME Latest Acute Coronary Syndrome by Category No in last 12 months No more than 12 months ago Acute MI 3 109 STEMI 1 3 NSTEMI 3 4 MI Aborted 0 0 Unstable Angina 1 10 Angina Other 0 0 Preinfarction Syndrome 0 0 Microinfarction 0 0 ACS 1 2 Other 4 20 TOTAL 13 148
  14. 14. HEROIN MISUSE MISUSE BY AGE THERAPY ENGAGEMENT HEPATITIS & HIV OTHER INFORMATION CHOOSE ANOTHER LIBRARY HEROIN MISUSE HOME The Heroin Misuse Summary sheet is a collection of tables showing useful information about patients who have misused heroin. To take a look at a table, please click the appropriate button above. Misuse by Age Therapy Engagement Hepatitis & HIV Other Information
  15. 15. HEROIN MISUSE MISUSE BY AGE THERAPY ENGAGEMENT HEPATITIS & HIV OTHER INFORMATION CHOOSE ANOTHER LIBRARY HEROIN MISUSE HOME People who have ever used heroin Percent of practice population by relevant age group Those in treatment in last eight weeks Percent of heroin misusers seen in last eight weeks Group/age sub-group of heroin misusers TOTAL PERCENT TOTAL PERCENT Number of heroin misusers 21 0% 0 0% Number under 18 years 1 0% 0 0% Number 18-30 years 11 2% 0 0% Number 30+ years 9 0% 0 0%
  16. 16. HEROIN MISUSE MISUSE BY AGE THERAPY ENGAGEMENT HEPATITIS & HIV OTHER INFORMATION CHOOSE ANOTHER LIBRARY HEROIN MISUSE HOME People who have ever used heroin Percent of practice population by relevant age group Those in treatment in last eight weeks Percent of heroin misusers seen in last eight weeks Therapy Engagement TOTAL PERCENT TOTAL PERCENT Evidence of engagement in therapy in past year 0 0.0% 0 0.0% Number on prescribed therapy 0 0.0% 0 0.0% Evidence of injecting drug misuse ever 0 0.0% 0 0.0% Evidence of multiple drug use including alcohol 4 19.0% 0 0.0%
  17. 17. HEROIN MISUSE MISUSE BY AGE THERAPY ENGAGEMENT HEPATITIS & HIV OTHER INFORMATION CHOOSE ANOTHER LIBRARY HEROIN MISUSE HOME People who have ever used heroin Percent of practice population by relevant age group Those in treatment in last eight weeks Percent of heroin misusers seen in last eight weeks Hepatitis & HIV TOTAL PERCENT TOTAL PERCENT Evidence of testing for Hepatitis B status ever 1 4.8% 0 0.0% No recorded Hepatitis B immunisation 19 90.5% 0 0.0% Incomplete Hepatitis B immunisation course 1 4.8% 0 0.0% Evidence of completing Hepatitis B immunisation course 1 4.8% 0 0.0% Evidence of Hepatitis C status testing 1 4.8% 0 0.0% Evidence of testing for HIV status 0 0.0% 0 0.0%
  18. 18. HEROIN MISUSE MISUSE BY AGE THERAPY ENGAGEMENT HEPATITIS & HIV OTHER INFORMATION CHOOSE ANOTHER LIBRARY HEROIN MISUSE HOME People who have ever used heroin Percent of practice population by relevant age group Those in treatment in last eight weeks Percent of heroin misusers seen in last eight weeks Other Information TOTAL PERCENT TOTAL PERCENT Evidence of adverse clinical outcome related to injecting drug misuse 2 9.5% 0 0.0% Evidence of unemployment or sickness benefit 7 33.3% 0 0.0% Evidence of successful outcome or naltrexone 0 0.0% 0 0.0% Number of heroin misuse treatment code without morbidity code 0 0.0% 0 0.0%
  19. 19. LDP – LOCAL DELIVERY PLAN The aim of the Local Delivery Plan analysis package for Smoking and Obesity is to enable practices to extract, process and send the required data specified by the Department of Health to your PCT. The data is broken down into tables that show the practice population, and the age/sex of all patients with a BMI and Smoking Status SMOKING OBESITY CHOOSE ANOTHER LIBRARY LDP HOME Smoking Obesity
  20. 20. LDP – LOCAL DELIVERY PLAN SMOKING OBESITY CHOOSE ANOTHER LIBRARY LDP HOME Age-Sex Breakdown of Patients aged 16 and over 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 134 84 74 85 150 158 185 191 192 180 169 148 245 1995 Males 131 104 86 87 125 181 175 170 198 196 143 137 205 1938 Totals 265 188 160 172 275 339 360 361 390 376 312 285 450 3933 Age-Sex Breakdown of Patients aged 16 and over with Latest Smoking Record in Last 15 Months or Never Smoked if aged 25 or over 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 108 73 66 80 129 145 167 168 173 164 161 144 237 1815 Males 86 66 61 67 99 150 132 139 159 172 132 121 196 1580 Totals 194 139 127 147 228 295 299 307 332 336 293 265 433 3395 Age-Sex Breakdown of Patients aged 16 and over where Latest Smoking Record in Last 15 Months Indicates Current Smoker 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 8 11 11 9 20 14 18 19 16 14 15 7 8 170 Males 8 10 17 11 13 18 23 14 16 21 13 10 15 189 Totals 16 21 28 20 33 32 41 33 32 35 28 17 23 359
  21. 21. LDP – LOCAL DELIVERY PLAN SMOKING OBESITY CHOOSE ANOTHER LIBRARY LDP HOME Age-Sex Breakdown of Patients aged 16 and over 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 134 84 74 85 150 158 185 191 192 180 169 148 245 1995 Males 131 104 86 87 125 181 175 170 198 196 143 137 205 1938 Totals 265 188 160 172 275 339 360 361 390 376 312 285 450 3933 Age-Sex Breakdown of Patients aged 16 and over with BMI Record in Last 15 Months 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 24 34 34 31 33 38 41 49 45 71 54 59 75 588 Males 19 11 25 17 23 46 43 35 65 63 57 60 81 545 Totals 43 45 59 48 56 84 84 84 110 134 111 119 156 1133 Age-Sex Breakdown of Patients aged 16 and with BMI Record in Last 15 Months of 30 or More or Obesity Recorded 16-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Grand Total Females 1 9 3 7 11 16 13 21 19 20 16 14 19 169 Males 0 2 4 4 4 21 10 15 25 27 19 16 19 166 Totals 1 11 7 11 15 37 23 36 44 47 35 30 38 335
  22. 22. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME The Safer Prescribing Library allows practices to examine their current prescribing to identify issues or even systems which might need attention. To take a look at some of the summary sheets available, please click the appropriate button above.
  23. 23. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POTENTIALLY INAPPROPRIATE PRESCRIBING Condition and Prescribed Drug Total Patients with history of Peptic Ulcer prescribed NSAID in Last 4 Months 3 Patients with history of Peptic Ulcer prescribed NSAID in Last 4 Months Without Gastroprotection 1 Active Asthma patient prescribed Beta Blocker in Last 12 Months 2 Women with Venous Thrombosis prescribed Oestrogen in Last 6 Months 1 Patient with history of Gout prescribed Diuretic in Last 4 Months 0 Patients with Aortic Stenosis prescribed Nitrate in Last 12 Months 2
  24. 24. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POTENTIALLY INADEQUATE MONITORING – PART 1 Methotrexate Total FBC LFT U&E Patients prescribed Methotrexate in Last 6 Months 12 Patients with test in Last 3 Months 5 4 6 Patients without test in Last 3 Months 7 8 6 Warfarin Total INR L2M No INR L2M 19 5 14 Lithium Total Serum Lith L3M No Serum Lith L3M 1 0 1 Amiodarone Total TFT LFT Patients prescribed Amiodarone in Last 6 Months 0 Patients with test in Last 12 Months 0 0 Patients without test in Last 12 Months 0 0
  25. 25. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POTENTIALLY INADEQUATE MONITORING – PART 2 ACEI & ACEII Total U&E L12M No U&E L12M Patients prescribed ACEI/ACEII in Last 6 Months 0 0 0 Azathioprine Total FBC L3M No FBC L3M Patients prescribed Azathrioprine in Last 6 Months 0 0 0 Penicillamine Total FBC L1M No FBC L1M Patients prescribed Pencillamine in Last 6 Months 0 0 0 Gold Total FBC L1M No FBC L1M Patients prescribed Gold in Last 6 Months 0 0 0 Statin Total LFT L12M No LFT L12M Patients prescribed Statin in Last 6 Months 1 1 0
  26. 26. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME INAPPROPRIATE DRUG FOR AGE Drugs Prescribed Total Patients (<16 yrs old) prescribed Aspirin 9 Patients (<12 yrs old) prescribed Tetracycline 4 Patients (<18 yrs old) prescribed SSRI 8 Patients (<18 yrs old) prescribed Phosphodiesterase Inhibitor (without evidence of Pulmonary Hypertension ) 3 Patients (>=75 yrs old) prescribed NSAID in Last 3 Months with Gastroprotection in Last 12 Months 6 Patients (>=75 yrs old) prescribed NSAID in Last 3 Months without Gastroprotection in Last 12 Months 13
  27. 27. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POTENTIALLY OVERLOOKED SAFETY INFORMATION Drugs Prescribed Total Prescription of Verapamil in Last 12 Months within 56 days of prescription of Beta Blocker 3 Prescription of NSAID in Last 12 Months within 56 days of prescription of Warfarin 1 Prescription of cipro/norfloxacin in Last 12 Months within 56 days of prescription of Theophylline 2 Prescription of Phosphodiesterase in Last 12 Months within 56 days of prescription of Nitrate 1 Prescription of Quinine in Last 12 Months within 56 days of prescription of Cardiac Glycoside 2 Prescription of Penicillin after allergy read coded 0 Prescription of Penicillin after adverse reacion read coded 2
  28. 28. SAFER PRESCRIBING POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE INADEQUATE MONITORING – PART 1 POSSIBLE INADEQUATE MONITORING – PART 2 POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE OVERLOOKED LABORATORY TESTS CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POTENTIALLY OVERLOOKED LABORATORY TEST RESULTS Hypothyroid Recording Total TSH level over 10 ever with no diagnosis of Hypothyroidism 5 Patients with Duplicated GFR Test Entries from Lablinks 0 Possible Retest Required One eGFR <30 ml/min in Last 12 Months 0 One eGFR 30 – 59 ml/min in Last 12 Months 28 Possible CKD Diagnosis Required 2 GFR Tests in Last 12 Months Latest <30ml/min and no CKD4/5 diagnosis code 0 2 GFR Tests in Last 12 Months Latest 30 - 59/min and no CKD3 diagnosis code 9 Diabetes Recording Glucose over 11 ever with no diagnosis of Diabetes 4
  29. 29. GRASP AF – (ATRIAL FIBRILLATION) ATRIAL FIBRILLATION & CHADS SCORE WARFARIN CHOOSE ANOTHER LIBRARY ATRIAL FIBRILLATION HOME What does GRASP-AF do? Provides a set of MIQUEST queries to identify, for your practice, patients with a diagnosis of AF who are not on warfarin The GRASP - AF tool will calculate their stroke risk using the validated CHADS2 scoring system. The tool will highlight patients with a CHADS2 score of 2 or more not receiving warfarin who would benefit from review to assess the issue of anti-coagulation. The tool does not assess contraindications to warfarin, the decision whether or not to start warfarin remains a clinical one. Click on the buttons above to see the information that is available on the CHART summary sheets. AF & CHADS Score Warfarin
  30. 30. GRASP AF – (ATRIAL FIBRILLATION) ATRIAL FIBRILLATION & CHADS SCORE WARFARIN CHOOSE ANOTHER LIBRARY ATRIAL FIBRILLATION HOME NO PERCENT Total No of Patients currently registered with Practice 5342 Total No of Patients with Atrial Fibrillation / Flutter 84 1.57% % of practice population aged 65+ with Atrial Fibrillation / Flutter 6.12% Risk Profile for Thromboembolism NO PERCENT CHADS2 Score = 0 8 9.52% CHADS2 Score = 1 23 27.38% CHADS2 Score > 1 53 63.10% TOTAL 84 100.00%
  31. 31. GRASP AF – (ATRIAL FIBRILLATION) ATRIAL FIBRILLATION & CHADS SCORE WARFARIN CHOOSE ANOTHER LIBRARY ATRIAL FIBRILLATION HOME Warfarin use in high risk patients (CHADS2 > 1) NO PERCENT Patients on warfarin 9 16.98% Patients not on warfarin 44 83.02% % of practice population aged 65+ with Atrial Fibrillation / Flutter 6.12% Patients on warfarin and anti-platelet agents in CHADS2 groups None Anti-platelet Warfarin Both CHADS2 Score = 0 8 0 0 0 CHADS2 Score = 1 17 2 4 0 CHADS2 Score > 1 39 5 4 5
  32. 32. MMR CATCHUP CAMPAIGN MMR SUMMARY SHEET CHOOSE ANOTHER LIBRARY MMR HOME The MMR CHART library has been designed to enable practices to identify patients that fall into the first three priority age groups specified in the Chief Medical Officer MMR Catch-Up Programme letter dated 6th August 2008. The library identifies patients under the age of nineteen that have had zero, one, or two MMR vaccinations to enable practices to review patient details for recall.
  33. 33. MMR CATCHUP CAMPAIGN MMR SUMMARY SHEET CHOOSE ANOTHER LIBRARY MMR HOME SUMMARY SHEET PLEASE ENSURE YOU READ THE ADVICE FILE BEFORE CONTINUING Age Group Total no registered Zero doses of MMR given Percentage One dose of MMR given Percentage Two doses of MMR given Percentage Age 2 years 43 6 13.95% 37 86.05% 0 0.00% Age 3 years 38 1 2.63% 16 42.11% 21 55.26% Age 4 years 40 4 10.00% 6 15.00% 30 75.00% Age 5 years 35 0 0.00% 2 5.71% 33 94.29% Age 6 years 45 5 11.11% 7 15.56% 33 73.33% Age 7 years 16 0 0.00% 4 25.00% 12 75.00% Age 8 years 22 1 4.55% 8 36.36% 13 59.09% Age 9 years 20 1 5.00% 6 30.00% 13 65.00% Age 10 years 25 1 4.00% 4 16.00% 20 80.00% Age 11 years 19 3 15.79% 7 36.84% 9 47.37% ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ Age 17 years 25 3 12.00% 6 24.00% 16 64.00% Age 18 years 28 1 3.57% 11 39.29% 16 57.14% TOTAL: Age 2 – 18 years 466 38 8.15% 143 30.69% 285 61.16%
  34. 34. IM&T DES DRUGS TO DISEASE AUDITS ALLERGY AUDIT CHOLECYSTECTOMY AUDIT HYSTERECTOMY AUDIT WRONG SEX AUDIT REFERRALS, LOCATION, SUMMARY AUDIT TOP LEVEL CODES AUDIT CHOOSE ANOTHER LIBRARY IM&T DES HOME The PRIMIS+ IM&T DES CHART Library was designed to help practices to achieve accredited data quality standards so that their information is fit for sharing in the NHS Care Records Service. This is a key objective of the IM&T DES. To see the summary sheets from some of the IM&T DES Queries, please click on the buttons above.
  35. 35. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME THE DIAGNOSES COVERED IN EACH OF THE DRUGS TO DIAGNOSES AUDITS ARE: DRUGS TO DIAGNOSIS AUDIT 1 Breast Cancer Glaucoma Pernicious Anaemia Hypothyroid DRUGS TO DIAGNOSIS AUDIT 2 Asthma / Urtcaria AF or Heart Failure Dysrhthmia Gout (1) Raised Intra Ocular Pressure DRUGS TO DIAGNOSIS AUDIT 3 Diabetes Epilepsy (1) Gout (2) Osteoporosis DRUGS TO DIAGNOSIS AUDIT 4 Depression (1) Inflammatory Bowel Disease Epilepsy (2) Psychosis Respiratory Disease DRUGS TO DIAGNOSIS AUDIT 5 Acne Depression (2) Inflammatory Bowel Disease Psychosis RA / Inflam Arthritis DRUGS TO DIAGNOSIS AUDIT 6 Migraine Psoriasis Prostate Cancer COPD
  36. 36. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 1 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Tamoxifen v Breast Cancer Diagnosis 17 16 1 94.1% Patients on Latanoprost / Timolol / Dorzolamide v Glaucoma Diagnosis 55 53 2 96.4% Patients on Hydroxocobalamin v Pernicious Anaemia Diagnosis 28 26 2 92.9% Patients on Levothyroxine v Hypothyroid Diagnosis 196 190 6 96.9%
  37. 37. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 2 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Montelukast v Asthma / Urtcaria Diagnosis 30 28 2 93.3% Patients on Digoxin v AF or Heart Failure Diagnosis 79 77 2 97.5% Patients on Amiodarone / Disopramide v Dysrhthmia Diagnosis 11 11 0 100.0% Patients on Allopurinol v Gout Diagnosis 53 51 2 96.2% Patients on Cartelol, Pilocarpine, Brinzolamide, Brimonidine v Raised Intra Ocular Pressure Diagnosis 23 21 2 91.3%
  38. 38. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 3 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Insulins and Other Antidiabetics except Metformin v Diabetes Diagnosis 170 170 0 100.0% Patients on Lamotrignine v Epilespy Diagnosis 13 12 1 92.3% Patients on Colchicine v Gout Diagnosis 13 10 3 76.9% Patients on Bisphosphonates v Osteoporosis Risk Diagnosis 67 59 8 88.1%
  39. 39. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 4 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Paroxetine v Depression Diagnosis 70 64 6 91.4% Patients on Predfoam Budesonide Rectal v Inflammatory Bowel Disease Diagnosis 3 3 0 100.0% Patients on Levetiracetam v Epilepsy Diagnosis 3 3 0 100.0% Patients on Clozapine / Risperidone / Olanzapine v Psychosis Diagnosis 42 42 0 100.0% Patients on Inhaled (Lung) Steroids v Respiratory Disease Diagnosis 565 544 21 96.3%
  40. 40. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 5 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Roaccutane/Tretinoin v Acne Diagnosis 2 2 0 100.0% Patients on Fluoxetine v Depression Diagnosis 123 118 5 95.9% Patients on Mesalazine v Inflammatory Bowel Disease Diagnosis 17 17 0 100.0% Patients on Depot Antipsychotics and Psychosis Diagnosis 9 8 1 88.9% Patients on Gold, Penicillamine or Leflunomide and RA / Inflam Arthritis Diagnosis 5 5 0 100.0%
  41. 41. IM&T DES – DRUGS TO DIAGNOSIS AUDITS DRUGS TO DIAGNOSIS AUDIT 1 DRUGS TO DIAGNOSIS AUDIT 2 DRUGS TO DIAGNOSIS AUDIT 3 DRUGS TO DIAGNOSIS AUDIT 4 DRUGS TO DIAGNOSIS AUDIT 5 DRUGS TO DIAGNOSIS AUDIT 6 IMT DES HOME DRUGS TO DIAGNOSIS HOME DRUGS TO DISEASE AUDIT 6 Total No. of Patients on the drug(s) No. with appropriate diagnosis No. without diagnosis Percentage with diagnosis Patients on Pizotifen v Migraine Diagnosis 22 18 4 81.8% Patients on Calcipotriol v Psoriasis Diagnosis 44 42 2 95.5% Patients on Bicalutamide / Buserelin / Goserelin / Flutamide v Prostate Cancer Diagnosis 10 10 0 100.0% Patients on Tiotropium v COPD Diagnosis 23 20 3 87.0%
  42. 42. IM&T DES ALLERGY AUDIT NON DRUG ALLERGY AUDIT DRUG ALLERGY AUDIT IMT DES HOME ALLERGY AUDIT HOME NON Drug Allergy Drug Allergy
  43. 43. IM&T DES ALLERGY AUDIT NON DRUG ALLERGY AUDIT DRUG ALLERGY AUDIT IMT DES HOME ALLERGY AUDIT HOME NON DRUG ALLERGY FROM MIQUEST TOTAL NUMBER RATE PER 1000 PATIENTS Total No. of Patients who have a Non Drug Allergy Code 139 18.7 Total No. of Patients with Food Allergy Codes 11 1.5 Total No. of Patients with Allergies to Venom (Bee & Wasp Stings) 10 1.3 Total No. of Patients with any other Non Drug Allergy entry 118 15.9 Total No. Non Drug Allergy entries 206 27.7 Total No. Food Allergy entries 19 2.6 Total No. Allergies to Venom (Bee & Wasp Stings) 15 2.0 Total No. Any other Non Drug Allergy entries 172 23.1
  44. 44. IM&T DES ALLERGY AUDIT NON DRUG ALLERGY AUDIT DRUG ALLERGY AUDIT IMT DES HOME ALLERGY AUDIT HOME DRUG ALLERGY FROM SYSTEM SUPPLIER REPORTS TOTAL NUMBER RATE PER 1000 PATIENTS Total No. of Patients who have Drug Allergies 22 2.2 Total No. of Drug Allergies 31 3.1 Total No. of Patients with Penicillin Allergy 16 1.6 Total No. of Patients with Antibiotic Allergy 16 1.6 Total No. of Patients with Gastro-Intestinal Drug Allergies 2 0.2 Total No. of Patients with Cardiovascular Drug Allergies 5 0.5 Total No. of Patients with CNS Drug Allergy 4 0.4 Total No. of Patients with Musculoskeletal Drug Allergy 5 0.5
  45. 45. IM&T DES CHOLECYSTECTOMY AUDIT DRUGS TO DISEASE AUDITS ALLERGY AUDIT CHOLECYSTECTOMY AUDIT HYSTERECTOMY AUDIT WRONG SEX AUDIT REFERRALS, LOCATION, SUMMARY AUDIT TOP LEVEL CODES AUDIT CHOOSE ANOTHER LIBRARY IM&T DES HOME CHOLECYSTECTOMY AUDIT TOTAL NUMBER OF PATIENTS WITH RECORD PERCENTAGE Total No. of Patients who have had a Cholecystectomy 151 Total No. with 1 entry 106 70.2% Total No. with 2 entries 20 13.2% Total No. with 3 entries 13 8.6% Total No. with more than 3 entries 12 7.9% TIME DIFFERENCE WHERE MULTIPLE ENTRIES Less than a month between first and last entry 19 12.6% One month to one year between first and last entry 20 13.2% Over one year between first and last entry 6 4.0% Total No. with a high level code added 6 4.0% Total No. Recorded as having an Endoscopic Cholecysectomy 62 41.1%
  46. 46. IM&T DES HYSTERECTOMY AUDIT DRUGS TO DISEASE AUDITS ALLERGY AUDIT CHOLECYSTECTOMY AUDIT HYSTERECTOMY AUDIT WRONG SEX AUDIT REFERRALS, LOCATION, SUMMARY AUDIT TOP LEVEL CODES AUDIT CHOOSE ANOTHER LIBRARY IM&T DES HOME HYSTERECTOMY AUDIT TOTAL NUMBER OF PATIENTS WITH RECORD PERCENTAGE Total No. of Patients who have had a Hysterectomy 330 Total No. with 1 entry 150 45.5% Total No. with 2 entries 92 27.9% Total No. with 3 entries 31 9.4% Total No. with more than 3 entries 57 17.3% TIME DIFFERENCE WHERE MULTIPLE ENTRIES Less than a month between first and last entry 37 11.2% One month to one year between first and last entry 69 20.9% Over one year between first and last entry 74 22.4% Total No. with a high level code added 4 1.2% Total No. Recorded as having a Cervical Smear after Hysterectomy 19 5.8%
  47. 47. IM&T DES WRONG SEX AUDIT FEMALE CODES IN MALE RECORDS MALE CODES IN FEMALE RECORDS IMT DES HOME WRONG SEX AUDIT HOME Female Codes In Male Records Male Codes In Female Records
  48. 48. IM&T DES WRONG SEX AUDIT FEMALE CODES IN MALE RECORDS MALE CODES IN FEMALE RECORDS IMT DES HOME WRONG SEX AUDIT HOME FEMALE CODES IN MALE RECORDS TOTAL NO. OF PATIENTS WITH RECORD RATE PER 1000 PATIENTS Total No. of Males with Female Codes 67 9.0 NO. OF PATIENTS WITH RECORD EVER NO. OF PATIENTS WITH RECORD IN LAST 6 MONTHS Males with any Female Codes 67 3 Males with Female Contraception Codes 0 0 Males with Pregnancy Process Codes (62%) 50 1 Males with Obstetric Codes (L%) 6 1 Males with Female Operation Codes 3 0 Males with Female Referral Codes 4 1 Males with Cervical Smear Codes 5 0
  49. 49. IM&T DES WRONG SEX AUDIT FEMALE CODES IN MALE RECORDS MALE CODES IN FEMALE RECORDS IMT DES HOME WRONG SEX AUDIT HOME MALE CODES IN FEMALE RECORDS TOTAL NO. OF PATIENTS WITH RECORD RATE PER 1000 PATIENTS Total No. of Females with Male Codes 5 0.7 NO. OF PATIENTS WITH RECORD EVER NO. OF PATIENTS WITH RECORD IN LAST 6 MONTHS Females with any Male Codes 5 0 Females with Male Operation Codes 3 0 Females with Male Disease Codes 2 0
  50. 50. IM&T DES REFERRALS & LOCATIONS & SUMMARIES AUDIT REFERRALS LOCATIONS SUMMARIES IMT DES HOME REFERRALS, LOCATION, SUMMARY HOME Referrals Locations Summaries
  51. 51. IM&T DES REFERRALS & LOCATIONS & SUMMARIES AUDIT REFERRALS LOCATIONS SUMMARIES IMT DES HOME REFERRALS, LOCATION, SUMMARY HOME REFERRALS TOTAL NUMBER RATE PER 1000 PATIENTS Total No. of Patients with Referral Codes in Last 12 Months 1414 190.1 Total No. of Patients with Medical Referral Codes in Last 12 Months 418 56.2 Total No. of Patients with Surgical Referral Codes in Last 12 Months 679 91.3 Total No. of Patients with Private Referral Codes in Last 12 Months 0 0.0 Total No. of Patients with Referral to Other Agencies Codes in Last 12 Months 372 50.0 Total No. of Patients with Uncategorised Referral Codes in Last 12 Months 128 17.2 Total No. of Medical Referral Codes in Last 12 Months 463 62.2 Total No. of Surgical Referral Codes in Last 12 Months 868 116.7 Total No. of Private Referral Codes in Last 12 Months 0 0.0 Total No. of Referral to Other Agencies Codes in Last 12 Months 549 73.8 Total No. of Uncategorised Referral Codes in Last 12 Months 128 17.2
  52. 52. IM&T DES REFERRALS & LOCATIONS & SUMMARIES AUDIT REFERRALS LOCATIONS SUMMARIES IMT DES HOME REFERRALS, LOCATION, SUMMARY HOME LOCATIONS (From Clinical Supplier System Reports) TOTAL NUMBER RATE PER 1000 PATIENTS Total No. of Surgery Encounters in Last 28 Days 1720 340.6 Total No. of Telephone Encounters in Last 28 Days 62 12.3 Total No. of Home Visits in Last 28 Days 32 6.3
  53. 53. IM&T DES REFERRALS & LOCATIONS & SUMMARIES AUDIT REFERRALS LOCATIONS SUMMARIES IMT DES HOME REFERRALS, LOCATION, SUMMARY HOME SUMMARY ONCE PER DIAGNOSIS (From Clinical Supplier System Reports) NO OF PATIENTS WITH RECORDS NO OF PATIENTS WITH A RECORD WITH SUMMARY FLAG PERCENT OF PATIENTS WITH SUMMARY FLAG Summaries for Cholecystectomies 0 0 0.0% Summaries for Chronic Bronchitis 2 2 100.0% Summaries for Hypothyroidism 0 0 0.0% Summaries for Colectomies 0 0 0.0% Summaries for Rheumatoid Arthritis 1 0 0.0% Summaries for Breast Cancer 0 0 0.0% Summaries for Essential Hypertension 6 5 83.3% Summaries for Ulcerative Colitis 0 0 0.0% Summaries for Multiple Sclerosis 0 0 0.0% Summaries for Parkinsons Disease 0 0 0.0% Summaries for Dementia 2 0 0.0% ↓ ↓ ↓ ↓ Summaries for Glaucoma 0 0 0.0%
  54. 54. TOP LEVEL CODES AUDIT DRUGS TO DISEASE AUDITS ALLERGY AUDIT CHOLECYSTECTOMY AUDIT HYSTERECTOMY AUDIT WRONG SEX AUDIT REFERRALS, LOCATION, SUMMARY AUDIT TOP LEVEL CODES AUDIT CHOOSE ANOTHER LIBRARY IM&T DES HOME TOP LEVEL CODES TOTAL NO. OF PATIENTS WITH TOP LEVEL CODE RATE PER 1000 PATIENTS Total No. of Patients with Top Level Codes 26 3.5 Total No. of Patients with [A….] Codes 0 0.0 Total No. of Patients with [B…. Or XE1vN] Codes 0 0.0 Total No. of Patients with [C…. Or Xa9AI] Codes 12 2.0 Total No. of Patients with [D…. Or X20Bj] Codes 0 0.0 Total No. of Patients with [E….] Codes 0 0.0 Total No. of Patients with [F…. Or X000E] Codes 4 1.0 Total No. of Patients with [G…. Or XE0UX] Codes 0 0.0 Total No. of Patients with [H….] Codes 2 0.0 Total No. of Patients with [J….] Codes 0 0.0 Total No. of Patients with [K…. Or X30Hb] Codes 0 0.0 ↓ ↓ ↓ Total No. of Patients with [Z….] Codes 0 0.0
  55. 55. PNEUMOCOCCAL PNEUMO SUMMARY SHEET – PART 1 PNEUMO SUMMARY SHEET – PART 2 CHOOSE ANOTHER LIBRARY PNEUMOCOCCAL HOME The aim of this query set is to support the Chief Medical Officer Immunisation Programme for older people and risk groups. The Pneumococcal (PPV) Vaccine Uptake CHART Library has been designed to provide the details of vaccinations given to people 65 and over and ‘At-risk groups' as per the Chief Medical Officer’s (CMO) Letter of 31st March 2005.
  56. 56. PNEUMOCOCCAL VACCINATION PNEUMO SUMMARY SHEET – PART 1 PNEUMO SUMMARY SHEET – PART 2 CHOOSE ANOTHER LIBRARY PNEUMOCOCCAL HOME PNEUMOCOCCAL VACCINATION UPTAKE SURVEY 2009 Patient age on 31 st March 2009 as defined using the Dates of Birth (DOB) below Number of patients registered in the day data is extracted Number of registered patients that have received the pneumococcal vaccine between 1 st April 2008 and 31 st March 2009 Number of patients that have received the pneumococcal vaccine at any time (including the last year) on or before 31 st March % Uptake (vaccinated in the last year) % Uptake (vaccinated anytime before 31 st March 09) Aged 65 and over 575 21 329 3.65% 57.22% Aged 2 to 15 750 0 1 0.00% 0.13% Aged 16 to 64 3925 4 107 0.10% 2.73% Aged 65 33 5 10 15.15% 30.30% 66 to 74 268 13 161 4.85% 60.07% 75 to 79 108 3 74 2.78% 68.52% 80+ 166 0 84 0.00% 50.60% No. of males aged 65 and over 269 11 145 4.09% 53.90% No. of females aged 65 and over 306 10 184 3.27% 60.13%
  57. 57. PNEUMOCOCCAL VACCINATION Same information as above is provided for Chronic Respiratory Disease, Chronic Heart Disease, Chronic Kidney Disease, Chronic Liver Disease, Diabetes, Immunosuppression, HIV Infection, Bone Marrow Transplant, Cochlear Implants, Cerebrospinal Fluid Leaks, Cancer on or after 1/4/ 2008, Asthma on continuous or repeated steroids. PNEUMO SUMMARY SHEET – PART 1 PNEUMO SUMMARY SHEET – PART 2 CHOOSE ANOTHER LIBRARY PNEUMOCOCCAL HOME PNEUMOCOCCAL VACCINATION UPTAKE SURVEY 2009 Patient age on 31 st March 2009 as defined using the Dates of Birth (DOB) below Number of patients registered in the day data is extracted Number of registered patients that have received the pneumococcal vaccine between 1 st April 2008 and 31 st March 2009 Number of patients that have received the pneumococcal vaccine at any time (including the last year) on or before 31 st March % Uptake (vaccinated in the last year) % Uptake (vaccinated anytime before 31 st March 09) Summary of Patients in one or more Risk Group(s) Aged 2 to 15 750 0 1 0.00% 0.13% Aged 16 to 64 3925 4 107 0.10% 2.73% Aged 65 33 5 10 15.15% 30.30% Patients with Asplenia or Dysfuction of the Spleen (re-immunisation recommended every 5 years) Aged 2 to 15 750 0 1 0.00% 0.13% Aged 16 to 64 3925 4 107 0.10% 2.73% Aged 65 33 5 10 15.15% 30.30%
  58. 58. MIACS SUMMARY SHEET CHARTS DATA SHEET MAIN MENU SUMMARY SHEET
  59. 59. CHART GRAPH EXAMPLES 1 – 2 – 3 CHARTS DATA SHEET MAIN MENU SUMMARY SHEET
  60. 60. CHART GRAPH EXAMPLES 1 – 2 – 3 CHARTS DATA SHEET MAIN MENU SUMMARY SHEET
  61. 61. CHART GRAPH EXAMPLES 1 – 2 – 3 CHARTS DATA SHEET MAIN MENU SUMMARY SHEET
  62. 62. MIACS DATASHEET CLICK HERE FOR MORE OF DATASHEET CHARTS DATA SHEET MAIN MENU SUMMARY SHEET Note – CHART can bring back either anonymised references or patient names
  63. 63. MIACS DATASHEET CLICK HERE FOR MORE OF DATASHEET CLICK HERE FOR MORE OF DATASHEET CHARTS DATA SHEET MAIN MENU SUMMARY SHEET Note – CHART can bring back either anonymised references or patient names
  64. 64. MIACS DATASHEET CLICK HERE FOR MORE OF DATASHEET CLICK HERE FOR MORE OF DATASHEET CHARTS DATA SHEET MAIN MENU SUMMARY SHEET Note – CHART can bring back either anonymised references or patient names
  65. 65. MIACS DATASHEET CLICK HERE FOR MORE OF DATASHEET CHARTS DATA SHEET MAIN MENU SUMMARY SHEET Note – CHART can bring back either anonymised references or patient names
  66. 66. CHART ONLINE CHART ONLINE is a database maintained by PRIMIS+. For specific libraries practices can upload data from CHART to this database. These libraries are currently: IM&T DES, MIACS, HEROIN MISUSE, ATRIAL FIBRILLATION The practices can then, via the internet, log into the CHART Online software and look at useful graphs which compare their results with those of their fellow practices. Results from other practices are anonymised. You can see some of these graphs by clicking the above buttons. EXAMPLE CHART 1 EXAMPLE CHART 2 EXAMPLE CHART 3 EXAMPLE CHART 4 MAIN MENU CHART ONLINE HOME
  67. 67. CHART ONLINE EXAMPLE CHART 1 EXAMPLE CHART 2 EXAMPLE CHART 3 EXAMPLE CHART 4 MAIN MENU CHART ONLINE HOME Chart showing patients with prescription of Tamoxifen and percentage with a diagnosis of Breast Cancer
  68. 68. CHART ONLINE Chart showing patients with pacemakers and whether this shows on GP’s summary screen when they starts consultation EXAMPLE CHART 1 EXAMPLE CHART 2 EXAMPLE CHART 3 EXAMPLE CHART 4 MAIN MENU CHART ONLINE HOME
  69. 69. CHART ONLINE Chart showing hysterectomy coding, including patients who have had hysterectomies coded more than once. EXAMPLE CHART 1 EXAMPLE CHART 2 EXAMPLE CHART 3 EXAMPLE CHART 4 MAIN MENU CHART ONLINE HOME
  70. 70. CHART ONLINE Chart showing Meniere’s disease and rate per 1000 EXAMPLE CHART 1 EXAMPLE CHART 2 EXAMPLE CHART 3 EXAMPLE CHART 4 MAIN MENU CHART ONLINE HOME

×